True North Therapeutics
South San Francisco
About True North Therapeutics
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $142.0M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2018)
- Website: truenorthrx.com
- Phone: (650) 872-4700
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/true-north-therapeutics-127238 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.